Danaher's unbroken four-quarter earnings beat streak and 124% free-cash-flow conversion attest to strong fundamental quality; the stock is just below its analyst-derived target with approximately 20% upside and a 3.25-to-1 risk/reward, though the confirmed long-term downtrend below the 200-day moving average and an RSI at overbought levels warrant caution about near-term entry timing.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Danaher has beaten earnings estimates in each of the past four consecutive quarters, with positive surprises of 6.45%, 1.99%, 9.78%, and 9.49% reading from most recent to oldest; a perfect four-quarter beat record signals that consensus estimates have been consistently and persistently set below actual results. This pattern of under-promising and over-delivering supports confidence that forward estimates may also be conservative. Earnings | Earnings beats continue, with at least three of the next four quarters recording positive EPS surprises; consensus estimates are revised upward following continued outperformance. | →Stable |
| CounterThe beat margins are modest—the most recent was 6.45% and the prior quarter only 1.99%—meaning any single guidance shortfall or execution miss could easily break the streak; moreover, recent analyst activity detected in the news may prompt updated, more accurate estimates that close the under-modeled gap and reduce future surprise potential. | ||
Free cash flow is 124% of net income, meaning the company converts more than all of its stated net earnings to cash, a level that indicates high-quality earnings with minimal accruals; the Piotroski F-Score is a perfect 9 out of 9, the highest attainable indication of financial soundness across profitability, leverage, and liquidity measures. Quality breakdown | FCF-to-net-income conversion remains above 100% and Piotroski F-Score is maintained at 8 or above over the next four quarters. | →Stable |
| CounterA FCF-to-net-income ratio above 100% can reflect favorable working capital timing or non-recurring items that reverse in subsequent periods; growth is characterized as weak in the bear case, and if the operational outlook does not improve, conversion may decline from its currently exceptional level. | ||
The stock is below its 200-day moving average with the moving average itself declining at -1.8% over 30 days—a configuration the momentum notes explicitly characterize as a confirmed downtrend; simultaneously, RSI at 74 is overbought, and the notes classify the current bounce as a bear rally rather than a durable momentum reversal. Momentum breakdown | Price breaks sustainably above the 200-day moving average and the 30-day MA slope turns positive, confirming the downtrend has reversed; RSI moderates to a neutral range without a sharp price selloff. | →Stable |
| CounterVolume accumulation (rising on-balance volume) and a momentum reading that has cleared the minimum threshold for a technical entry are signs of genuine near-term buying interest; the death cross configuration is noted as recovering, suggesting the downtrend may already be in the process of reversing rather than deepening. | ||
Danaher has beaten earnings estimates in each of the past four consecutive quarters, with positive surprises of 6.45%, 1.99%, 9.78%, and 9.49% reading from most recent to oldest; a perfect four-quarter beat record signals that consensus estimates have been consistently and persistently set below actual results. This pattern of under-promising and over-delivering supports confidence that forward estimates may also be conservative.
→Stable- Expectation
- Earnings beats continue, with at least three of the next four quarters recording positive EPS surprises; consensus estimates are revised upward following continued outperformance.
CounterThe beat margins are modest—the most recent was 6.45% and the prior quarter only 1.99%—meaning any single guidance shortfall or execution miss could easily break the streak; moreover, recent analyst activity detected in the news may prompt updated, more accurate estimates that close the under-modeled gap and reduce future surprise potential.
Free cash flow is 124% of net income, meaning the company converts more than all of its stated net earnings to cash, a level that indicates high-quality earnings with minimal accruals; the Piotroski F-Score is a perfect 9 out of 9, the highest attainable indication of financial soundness across profitability, leverage, and liquidity measures.
→Stable- Expectation
- FCF-to-net-income conversion remains above 100% and Piotroski F-Score is maintained at 8 or above over the next four quarters.
CounterA FCF-to-net-income ratio above 100% can reflect favorable working capital timing or non-recurring items that reverse in subsequent periods; growth is characterized as weak in the bear case, and if the operational outlook does not improve, conversion may decline from its currently exceptional level.
The stock is below its 200-day moving average with the moving average itself declining at -1.8% over 30 days—a configuration the momentum notes explicitly characterize as a confirmed downtrend; simultaneously, RSI at 74 is overbought, and the notes classify the current bounce as a bear rally rather than a durable momentum reversal.
→Stable- Expectation
- Price breaks sustainably above the 200-day moving average and the 30-day MA slope turns positive, confirming the downtrend has reversed; RSI moderates to a neutral range without a sharp price selloff.
CounterVolume accumulation (rising on-balance volume) and a momentum reading that has cleared the minimum threshold for a technical entry are signs of genuine near-term buying interest; the death cross configuration is noted as recovering, suggesting the downtrend may already be in the process of reversing rather than deepening.
▸ Show 1 more pillar▾ Show fewer
With approximately 20% of upside remaining to the $219.85 analyst-derived target and a reward-to-risk ratio of 3.25-to-1, the current price offers a materially favorable setup; analyst consensus reflects 33% upside and the asymmetry bar is met, making this a geometry worth monitoring for a better technical entry.
→Stable- Expectation
- Price advances toward the $219.85 target over the next 12 months; the reward-to-risk ratio remains above 1.5-to-1 as the position appreciates.
CounterAn elevated put/call ratio of 1.42 and the confirmed downtrend below the 200-day moving average represent meaningful near-term obstacles; a favorable reward/risk geometry does not prevent further price deterioration if the technical picture worsens before the fundamental thesis plays out, and the overbought RSI at 74 raises the probability of a near-term pullback.
Danaher Corporation (DHR) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Diagnostics & Research
Sell if holding. Multiple concerning factors at $188.87: Below 200-MA, MA slope -1.9%/30d (confirmed downtrend); Weak growth.
Danaher develops instruments, consumables, and services for the biotechnology, life sciences, and diagnostics sectors across approximately 50 countries, organized in three segments under those names. Revenue skews toward recurring consumables and services, with approximately 59%... Read more
Sell if holding. Multiple concerning factors at $188.87: Below 200-MA, MA slope -1.9%/30d (confirmed downtrend); Weak growth. Chart setup: Death cross but MACD improving, RSI 63. Score 5.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 27d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-25Recent Developments — Danaher Corporation
Latest news
- NEWS Danaher (DHR) Downgraded by Citigroup -- Price Target Lowered to $95 - GuruFocus — GuruFocus negative
- NEWS Danaher (DHR) Receives Buy Rating from Citi with $230 Price Targ - GuruFocus — GuruFocus positive
- NEWS Danaher Corporation Shs Cert Deposito Arg Repr 0.018518518 Sh Balance Sheet – BCBA:DHR.CI - TradingView — TradingView neutral
- NEWS Jefferies Financial Group Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price - MarketBeat — MarketBeat negative
- NEWS Sivik Global Healthcare LLC Trims Stock Holdings in Danaher Corporation $DHR - MarketBeat — MarketBeat neutral
Generated 2026-06-25T04:07:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $188.87: Below 200-MA, MA slope -1.9%/30d (confirmed downtrend); Weak growth. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $178.33. Score 5.5/10, moderate confidence.
Take-profit target: $218.11 (+15.5% upside). Prior stop was $178.33. Stop-loss: $178.33.
Weak growth; Below 200-MA, MA slope -1.9%/30d (confirmed downtrend).
Danaher Corporation trades at a P/E of 34.8 (forward 19.3). TrendMatrix value score: 5.7/10. Verdict: Sell.
30 analysts cover DHR with a consensus score of 4.3/5. Average price target: $242.
What does Danaher Corporation do?Danaher develops instruments, consumables, and services for the biotechnology, life sciences, and diagnostics sectors...
Danaher develops instruments, consumables, and services for the biotechnology, life sciences, and diagnostics sectors across approximately 50 countries, organized in three segments under those names. Revenue skews toward recurring consumables and services, with approximately 59% of 2025 sales from non-US customers; the company employs approximately 60,000 people across more than 15 operating companies.